Integrase strand transfer inhibitors (INSTIs) are a class of antiretroviral drugs with high virologic efficacy and excellent tolerability. Recent evidence showed a possible link of dolutegravir-based regimens with weight gain, and a relationship between raltegravir use and changes in adipose tissue density and metabolic abnormalities, with an increased cardiovascular risk, has been suggested. We describe a case where dolutegravir monotherapy led to a decrease in adipose tissue density.
NorwoodJTurnerCBofillC, et al.Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr2017;
15: 527–531.
3.
BakalDCoelhoLLuzP, et al.Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors. J Antimicrob Chemoter2018;
73: 2177–2185.
4.
BourgiKRebeiroPFTurnerM, et al.Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis2020;
70: 1267–1274.
5.
VenterWDFMoorhouseMSokhelaS, et al.Dolutegravir plus two different pro-drugs of tenofovir to treat HIV. N Engl J Med2019;
381: 803–815.
6.
RizzardoSLanzafameMLattuadaE, et al.Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients. AIDS2019;
33: 1673–1674.
7.
KovariHLedergerberBPeterU, et al.Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis2009;
49: 626–635.
8.
ShusterAPatlasMPinthusJH, et al.The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol2012;
85: 1–10.
9.
MurphyRARegisterTCShivelyCA, et al.Adipose tissue density, a novel biomarker predicting mortality risk in older adults. J Gerontol A Biol Sci Med Sci2014;
69: 109–117.
10.
WellsMMLiZAddemanB, et al.Computed tomography measurement of hepatic steatosis: Prevalence of hepatic steatosis in a Canadian population. Can J Gastroenterol Hepatol2016;
2016: 4930987.
11.
HillAWatersLPozniakA.Are new antiretroviral treatments increasing the risks of clinical obesity?J Virus Erad2019;
5: 41–43.
12.
GorwoodJBourgeoisCPourcherV, et al. Integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in adipose tissue and adipocytes (abstract PS3/4). In: Abstracts of 17th European AIDS conference, Basel, 6--9 November 2019.
13.
DebroyPLakeJEMoserC, et al. Antiretroviral therapy initiation is associated with decreased visceral and subcutaneous adipose tissue density in people living with HIV. Clin Infect Dis. Epub ahead of print 28 February 2020. DOI:10.1093/cid/ciaa196.
14.
GaldamezRGarcíaJAFernándezM, et al.Short-term increase in risk of overweight and concomitant systolic blood pressure elevation in treatment-naïve persons starting INSTI-based antiretroviral therapy. Open Forum Infect Dis2019;
6: ofz491.
